Everolimus 2nd line palliative biotherapy in a patient with metastatic renal cell cancer with clinically significant manifestation of paraneoplastic polyglobulia
2013
Abstract
In a case report the author describes his own experience with the side effect of palliative biological treatment mTOR inhibitor (everolimus), which is a paraneoplastic polyglobulia. This side-effect of treatment with everolimus in patients with marked rise in hemoglobin levels of more than 190 g / l requiring treatment in terms of design and blood venipuncture and reduction of dose of everolimus.